Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.
Holzerová M, Faber E, Veselovská J, Urbánková H, Balcárková J, Rozmanová S, Voglová J, Muzík J, Chroust K, Indrák K, Jarosová M; CAMELIA-Chronic Myeloid Leukaemia Project. Holzerová M, et al. Among authors: faber e. Cancer Genet Cytogenet. 2009 May;191(1):1-9. doi: 10.1016/j.cancergencyto.2008.12.013. Cancer Genet Cytogenet. 2009. PMID: 19389502
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response.
Faber E, Friedecký D, Micová K, Divoká M, Katrincsáková B, Rozmanová S, Jarosová M, Indrák K, Adam T. Faber E, et al. Int J Hematol. 2010 Jun;91(5):897-902. doi: 10.1007/s12185-010-0576-y. Epub 2010 May 1. Int J Hematol. 2010. PMID: 20437122
Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry.
Faber E, Mužík J, Koza V, Demečková E, Voglová J, Demitrovičová L, Chudej J, Markuljak I, Cmunt E, Kozák T, Tóthová E, Jarošová M, Dušek L, Indrák K. Faber E, et al. Eur J Haematol. 2011 Aug;87(2):157-68. doi: 10.1111/j.1600-0609.2011.01637.x. Eur J Haematol. 2011. PMID: 21535160
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P, Faber E, Divoka M, Rozmanova S, Friedecky D, Jarosova M, Indrak K. Rohon P, et al. Among authors: faber e. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Jun;157(2):181-8. doi: 10.5507/bp.2011.059. Epub 2011 Nov 30. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013. PMID: 22660209 Free article.
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, Karas M, Faber E, Demečková E, Michalovičová-Sninská Z, Voglová J, Demitrovičová L, Mikušková E, Tóthová E, Chudej J, Markuljak I, Cmunt E, Moravcová J, Dvořáková D, Michalová K, Jarošová M, Sťastná MM, Cetkovský P, Dušek L, Koza V, Trněný M, Indrák K. Klamová H, et al. Among authors: faber e. Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21. Cancer Med. 2013. PMID: 23634289 Free PMC article.
249 results